ANTON DRAGONETTI: Open Payments
NPI 1972091221 · ST PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$839 in 41 payments from 7 companies in 2025. Trend: 2023 $1,873 · 2024 $367 · 2025 $839
Food & beverage: $839
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $372 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $135 |
| Corium, LLC | 5 | $130 |
| Neos Therapeutics, LP | 5 | $82 |
| E.R. Squibb & Sons, L.L.C. | 2 | $48 |
| Alkermes, Inc. | 2 | $48 |
| Bausch Health US, LLC | 1 | $25 |
Products named: INGREZZA, CAPLYTA, Azstarys, Adzenys XR-ODT, COBENFY, ARISTADA, APLENZIN, EXXUA.
Industry payments across FL — which companies pay providers there.
